Efficacy and Safety of Apatinib Combined with S-1 in Treatment of Advanced Gastric Cancer and its Effect on Inflammatory Response and Immune Function
LATIN AMERICAN JOURNAL OF PHARMACY(2019)
摘要
This study aimed to investigate the efficacy and safety of apatinib combined with tegafurgimeracil-oteracil potassium capsule (S-1) in treatment of patients with advanced gastric cancer and its effect on inflammatory response and immune function. Seventy-two advanced gastric cancer patients failing in first-line treatment were randomly divided into control group (38 cases) and observation group (34 cases). The control group was treated with S-1, and the observation group was treated with apatinib based on S-1. The therapeutic course was four weeks (three weeks of administration, followed by one week of withdrawal). After three therapeutic courses, the short-term objective remission rate and clinical benefit rate in observation group were significantly higher than those in control group, respectively (P < 0.05). Compared with control group, in observation group the serum levels antigen 19-9, carcinoembryonic antigen, tumor supplied group of factors, tumor necrosis factor-alpha, interleukin-6, and interleukin-10 were significantly decreased, respectively (P < 0.05 or P < 0.01), the peripheral blood CD4(+) level and CD4(+)/CD8(+) ratio were significantly increased, respectively (P < 0.01), the mean time-to-progression in 1-year follow-up was significantly shortened, and the mean overall survival was significantly prolonged (P < 0.01). Compared with single use of S-1, the combined use of apatinib and S-1 can further inhibit the inflammatory response, enhance the immune function, and improve the therapeutic efficacy for advanced gastric cancer patients.
更多查看译文
关键词
advanced gastric cancer,apatinib,immune function,inflammatory factors,S-1
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要